SAGIMET BIOSCIENCES INC-A (SGMT)
US7867001049 - Common Stock
The market is buzzing with gapping stocks on Monday. Let's uncover which stocks are experiencing notable gaps during today's session.
Which stocks are gapping on Monday?
Sagimet Biosciences to Participate in the Piper Sandler 36th Annual Healthcare Conference
Sagimet Biosciences to Participate in the Piper Sandler 36th Annual Healthcare Conference
SAN MATEO, Calif., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Sagimet, Nasdaq: SGMT), a clinical-stage biopharmaceutical company...
Sagimet Biosciences Presents Clinical Denifanstat and Preclinical FASN Inhibitor Data at AASLD - The Liver Meeting® 2024
Sagimet Biosciences Reports Third Quarter 2024 Financial Results and Provides Corporate Updates
Sagimet Biosciences Reports Third Quarter 2024 Financial Results and Provides Corporate Updates
Denifanstat received Breakthrough Therapy designation from FDA for MASH Results from Phase 2b FASCINATE-2 study of denifanstat published in The Lancet...
Ascletis Completes Enrollment of Phase III Trial of ASC40 (Denifanstat) Once-Daily Oral Tablet for Treatment of Acne
/PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") today announces completion of enrollment of 480 patients for Phase III clinical trial of ASC40...
Sagimet Biosciences to Participate in the UBS Global Healthcare Conference
Sagimet Biosciences to Participate in the UBS Global Healthcare Conference
SAN MATEO, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Sagimet, Nasdaq: SGMT), a clinical-stage biopharmaceutical company...
Madrigal Catapults After Novo's Wegovy Proves It's No 'Silver Bullet' In MASH
Madrigal sells an approved MASH treatment that blasted third-quarter sales views out of the water.
Sagimet Biosciences Announces Successful Completion of End-of-Phase 2 Interactions with FDA on the Development of Denifanstat for MASH; Phase 3 Program Initiation Expected by End of 2024
The planned registration program consists of two double-blind, placebo-controlled multicenter Phase 3 trials, FASCINATE-3 and FASCINIT, to evaluate the...
Sagimet Biosciences Announces Upcoming Presentations at AASLD - The Liver Meeting® 2024
Sagimet Biosciences Announces Upcoming Presentations at AASLD - The Liver Meeting® 2024
SAN MATEO, Calif., Oct. 16, 2024 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Sagimet, Nasdaq: SGMT), a clinical-stage biopharmaceutical company...
Sagimet Biosciences Announces Publication of Results from Phase 2b FASCINATE-2 Clinical Trial of Denifanstat in Biopsy-Confirmed F2/F3 MASH in The Lancet Gastroenterology & Hepatology
- Treatment with denifanstat achieved statistically significant and clinically meaningful improvements in disease activity, MASH resolution and fibrosis --...
Sagimet Receives FDA Breakthrough Therapy Designation for Denifanstat in MASH
Sagimet Receives FDA Breakthrough Therapy Designation for Denifanstat in MASH
Supported by positive data from Phase 2b FASCINATE-2 trial of denifanstat in patients with MASH Preparations are ongoing to initiate Phase 3 program for...
Sagimet Biosciences to Present at the H.C. Wainwright 8th Annual MASH Virtual Conference and Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN MATEO, Calif., Oct. 01, 2024 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Sagimet, Nasdaq: SGMT), a clinical-stage biopharmaceutical company...
Sagimet Announces Oral Presentation at the 8th Annual MASH Drug Development Summit
Sagimet Announces Oral Presentation at the 8th Annual MASH Drug Development Summit
SAN MATEO, Calif., Sept. 12, 2024 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Sagimet, Nasdaq: SGMT), a clinical-stage biopharmaceutical company...
Monday Sector Leaders: Biotechnology, Drugs
Sagimet Biosciences to Participate in Two Upcoming Investor Conferences
SGMT Stock Earnings: Sagimet Biosciences Beats EPS for Q2 2024
SGMT stock results show that Sagimet Biosciences beat analyst estimates for earnings per share the second quarter of 2024.
SGMT Stock Earnings: Sagimet Biosciences Beats EPS for Q2 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Sagimet Biosciences (NASDAQ:SGMT) just reported results for the second quarter ...
Sagimet Biosciences Reports Second Quarter 2024 Financial Results and Provides Corporate Updates
Sagimet Biosciences Reports Second Quarter 2024 Financial Results and Provides Corporate Updates
Denifanstat Phase 2b FASCINATE-2 clinical trial 52-week data was presented in June at the European Association for the Study of the Liver (EASL) Congress ...
Sagimet Biosciences Announces Appointment of Anne Phillips and Jennifer Jarrett to its Board of Directors
Sagimet Biosciences Announces Appointment of Anne Phillips and Jennifer Jarrett to its Board of Directors
SAN MATEO, Calif., Aug. 01, 2024 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Sagimet, Nasdaq: SGMT), a clinical-stage biopharmaceutical company...
Sagimet Biosciences to Host Conference Call and Webcast to Discuss Recently Presented Data from ITT and F3 Patient Population in Phase 2b FASCINATE-2 Clinical Trial of Denifanstat
Call scheduled on Thursday, June 13, 2024 at 9.30 AM PT / 12:30 PM ET
Sagimet Biosciences to Host Conference Call and Webcast to Discuss Recently Presented Data from ITT and F3 Patient Population in Phase 2b FASCINATE-2 Clinical Trial of Denifanstat
Call scheduled on Thursday, June 13, 2024 at 9.30 AM PT / 12:30 PM ET...
Sagimet Biosciences Presents Data from ITT and F3 Patient Population in Phase 2b FASCINATE-2 Clinical Trial of Denifanstat at EASL International Liver Congress 2024
Denifanstat achieved statistically significant results on primary and secondary liver biopsy endpoints in the ITT population, including both histology...